Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.

Saved in:
Bibliographic Details
Title: Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Authors: Raghav KPS; MD Anderson Cancer Center, Houston, TX., Guthrie KA; SWOG Statistics and Data Management Center, Seattle, WA.; Fred Hutchinson Cancer Center, Seattle, WA., Tan B Jr; Washington University Siteman Cancer Center, St Louis, MO., Denlinger CS; Fox Chase Cancer Center, Philadelphia, PA., Fakih M; City of Hope National Medical Center, Duarte, CA., Overman MJ; MD Anderson Cancer Center, Houston, TX., Dasari NA; MD Anderson Cancer Center, Houston, TX., Corum LR; University of Kansas Cancer Center-MCA Rural MU NCORP/Olathe Health Cancer Center, Olathe, KS., Hicks LG; Baptist Health Cancer Research Network/Baptist Health Lexington, Lexington, KY., Patel MS; CORA NCORP, CommonSpirit Health Research Institute/Cancer Center at Saint Joseph's, Phoenix, AZ., Esparaz BT; Heartland Cancer Research NCORP/Cancer Care Specialists of Illinois, Decatur, IL., Kazmi SM; University of Texas Southwestern Medical Center/Parkland Memorial Hospital, Dallas, TX., Alluri N; Pacific Cancer Research Consortium NCORP/St Luke's Cancer Institute, Boise, ID., Colby S; SWOG Statistics and Data Management Center, Seattle, WA.; Fred Hutchinson Cancer Center, Seattle, WA., Gholami S; UC Davis Comprehensive Cancer Center, Sacramento, CA., Gold PJ; Swedish Cancer Institute, Seattle, WA., Chiorean EG; Fred Hutchinson Cancer Center, Seattle, WA.; University of Washington School of Medicine, Seattle, WA., Kopetz S; MD Anderson Cancer Center, Houston, TX., Hochster HS; Rutgers-Cancer Institute, New Brunswick, NJ., Philip PA; Wayne State University/Henry Ford Cancer Institute, Detroit, MI.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Apr 10; Vol. 43 (11), pp. 1348-1357. Date of Electronic Publication: 2025 Jan 06.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO-24-01710